Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal

Inclusion Criteria:

* Subject can provide written informed consent.
* Chronic non-cancer pain diagnosis such as low back pain, chronic neck pain, osteoarthritis, and prolonged post-surgical pain with daily pain for a minimum of 6 months.
* Self-reported use of prescribed oral opioid medication(s) (tablets, pills or capsules) of at least 50 morphine mg equivalent (MME) but no higher than 240 mg MME daily or near daily (≥5 days per week) for at least 12 weeks and seeking to discontinue their opioid medication.
* Willing to be treated with non-opioid treatments for pain (in addition to opioid being tapered) for duration of study.
* Willing to abstain from alcohol use during the study.
* Willing to partner with his or her pain physician on a subject-centered pain management plan during the study.
* In generally good health, in the opinion of the Investigator, other than the underlying chronic pain syndrome
* Women of childbearing potential must have a negative pregnancy test at Screening.
* Non-pregnant, non-lactating women who are postmenopausal, naturally or surgically sterile, or who agree to use acceptable contraceptive methods throughout the course of the study.
* Other criteria will be discussed in detail with potential subjects by Site Investigator

Exclusion Criteria:

* Has a primary diagnosis of complex regional pain syndrome, central neuropathic pain, somatoform pain syndromes, acute nerve root compression, any acute or progressive infectious, inflammatory, or neurological process.
* Taking methadone, buprenorphine, fentanyl rapid acting products, tapentadol, tramadol, butorphanol, meperidine, or levorphanol for any reason
* Liver disease that requires medication or medical treatment, and/or AST or ALT levels greater than 3 x ULN.
* Gastrointestinal or renal disease, which would significantly impair absorption, metabolism or excretion of study drug, or would require medication or medical treatment.
* Has a diagnosis of epilepsy or history of seizures.
* Cardiovascular abnormalities at Screening and before randomization (stable hypertension permitted)
* Self-reported or evidence of opioid use disorder (OUD) or other substance use disorder within last 12 months
* Any severe or unstable psychiatric disorder including post-traumatic stress disorder, schizophrenia, bipolar disorder, major depression, substance abuse, or suicidality as determined by the Investigator.
* Subject answers "yes" to "suicidal ideation" in prior 24 months to any items 1 through 5 on the C-SSRS, or subject answers "yes" to any lifetime "suicidal behavior" item on the C-SSRS.
* Any anticipated or scheduled surgery during the study period or within 30 days before Screening.
* Other criteria will be discussed in detail with potential subjects by site Investigator